Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
Introduction Nuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety fr...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
European Centre for Disease Prevention and Control
2024-12-01
|
| Series: | Eurosurveillance |
| Assuntos: | |
| Acceso en liña: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.50.2400164 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|